New antiepileptic drugs: Comparative studies of efficacy and cognition
- 42 Downloads
Over the past 10 years, the Food and Drug Administration has approved eight prophylactic antiepileptic drugs (AEDs). Although the goal of universal seizure control without side effects has not been reached, the tolerability of medications has improved. This paper reviews the AEDs introduced since 1993 and tries to objectively present comparative data obtained in double-blind studies.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Arunkumar G, Wyllie E, Kotagal P, Ong HT, Gilliam F: Parent- and patient validated content for pediatric quality-of-life. Epilepsia 2000, 41:1474–1484. This was a study to validate a parent and child questionnaire regarding the quality of life in children with epilepsy. A limited number of domains were deemed important. More importantly, the tool provides insight into family, and not physician, concerns.PubMedCrossRefGoogle Scholar
- 8.Bourgeois BF: New antiepileptic drugs in children: which ones for which seizures? Clin Neuropharmacol 2000, 23:119–132. A detailed review of the new antiepiletpic medications. It provides the details of issues not covered in this paper, including the studies leading to approval, reported side effects, and pharmacology, including dosing suggestions. The author provides his opinion of what drugs should be utilized and when.PubMedCrossRefGoogle Scholar
- 11.Karceski S, Morrell M, Carpenter D: The expert consensus guideline series. Treatment of epilepsy. Epilepsy Behav 2001, 2:A1-A50. This is an interesting study if one wants to know what one’s colleagues are doing. A large number of scenarios have been sent to the experts as to what antiepileptic drug they would utilize. The responses are tallied and provided in an easy to read form. Good approach and science, but based on opinion.CrossRefGoogle Scholar
- 13.Mattson RH, Cramer JA, Collins JF, and the Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group: A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonicclonic seizures in adults. N Engl J Med 1992, 327:765–771.PubMedCrossRefGoogle Scholar
- 15.Lindberger M, Alenius M, Frisén L, et al., on behalf of the GREAT Study Investigators Group: Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. Epilepsia 2000, 41:1289–1295.PubMedGoogle Scholar
- 25.Kwan P, Brodie MJ: Early identification of refractory epilepsy. N Engl J Med 2000, 342:314–319. The paper has important observations, including that the new drugs may not be adding much to our ability to make patients seizure free. Clearly, this approach will need to be constantly updated as even newer drugs are increasingly used. Also important is the finding that persons not responding to the first antiepileptic drugs probably have something quite wrong with their brain, and the chances of becoming seizure-free with any drug are small. Indirectly supports the argument for early surgical intervention.PubMedCrossRefGoogle Scholar
- 28.Baker GA, Hesdon B, Marson AG: Quality-of-life and behavioral measures in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards. Epilepsia 2000, 41:1357–1363. A study performed about studies. Randomized controlled trials of antiepileptic drugs were reviewed to evaluate the methodologies used for assessing mood and quality of life. Concerns are expressed regarding the validity of the measures in the epilepsy population and failure to review previously defined methods (52 different exams were used in 46 trials).PubMedCrossRefGoogle Scholar
- 34.Meador KJ, Loring DW, Ray PG, et al.: Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology 2001, 56:1177–1182. The study is not unique in its use of normal paid volunteers to assess the effects of a medication. The methodology of which tools are used in assessing the impact of the antiepilpetic drugs, however, rivals the best of any study. Many of the tasks have previously been demonstrated to be sensitive to these effects and a detailed description is provided.PubMedGoogle Scholar
- 35.Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW: Lamotrigine therapy for autistic disorder: a randomized, doubleblind, placebo-controlled trial. J Autism Dev Disord 2001, 31:175–181. Not an important study regarding the impact of lamotrignine therapy on autism. However, the observation that parents report significant improvement in spite of objective studies not demonstrating changes raises questions regarding reports of medication side effects in drug trials, or perhaps the ability of standardized tests to demonstrate what they purport to do.PubMedCrossRefGoogle Scholar
- 36.Cramer JA, Arrigo C, Van Hammee G, Gauer LJ, Cereghino JJ, for the N132 Study Group: Effect of levetiracetam on epilepsyrelated quality of life. Epilepsia 2000, 41:868–874. This study assesses the effects of levetiracetam upon the quality of life in patients with partial seizures. The importance of the paper is the clear impact of decreasing seizures in a trial and how it can influence apparent objective measures of overall functioning, not specifically from drug effects on the brain.PubMedCrossRefGoogle Scholar